Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

CONCLUSIONS: In diabetic patients with STEMI undergoing primary PCI, intracoronary abciximab may improve clinical outcomes as compared with standard intravenous use. These findings require confirmation in a dedicated randomized trial.
PMID: 26071862 [PubMed - as supplied by publisher]

Source: Vascular Pharmacology - June 10, 2015 Category: Drugs & Pharmacology Authors: Piccolo R, Eitel I, Galasso G, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F Tags: Vascul Pharmacol Source Type: research